Valuation: Silence Therapeutics plc

Market Cap 358M 479M 420M 388M 679M 45.86B 693M 4.66B 1.81B 22.44B 1.8B 1.76B 77.9B P/E 2026 *
-17x
P/E 2027 * -15.1x
Enterprise Value 212M 283M 248M 229M 402M 27.12B 410M 2.76B 1.07B 13.27B 1.06B 1.04B 46.07B EV / Sales 2026 *
84.9x
EV / Sales 2027 * 31.7x
Free-Float
69.36%
Yield 2026 *
-
Yield 2027 * -
1 day-6.06%
1 week-9.19%
Current month-13.16%
1 month+53.05%
3 months+62.99%
6 months+64.40%
Current year+56.83%
1 week 9.42
Extreme 9.4234
11.06
1 month 5.88
Extreme 5.88
11.06
Current year 4.19
Extreme 4.19
11.06
1 year 4.19
Extreme 4.19
11.06
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
27.72
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 14/12/2025
Director of Finance/CFO 54 21/02/2022
Chief Tech/Sci/R&D Officer - 01/01/2021
Director TitleAgeSince
Director/Board Member 63 21/06/2018
Chairman 72 01/12/2019
Director/Board Member 54 18/12/2025
Date Insider Type Main position Quantity % Market Cap.
01-02Free

Director

90,000 0.0635%
01-02Free

Director

90,000 0.0635%
01-02Free

Chief Financial Officer

375,000 0.2646%
Change 5-day change 1-year change 3-year change Capi.($)
-6.06%-9.19%+61.34%+59.45% 479M
-0.24%+1.85%+3.13%+8.40% 49.74B
-0.82%+0.39%+416.60%+591.84% 40.49B
-3.14%+3.13%+22.65%+55.74% 34.35B
-2.97%-0.61%+22.80%-7.96% 34.75B
-0.79%+2.02%+3.83%+36.42% 26.98B
+3.02%+2.65% - - 16.58B
-4.26%-3.62%+62.44%+116.67% 15.6B
-2.35%+6.14%+103.33%+101.18% 14.27B
-2.70%-2.04%+12.37%+17.77% 13.76B
Average -2.15%+2.83%+78.72%+108.83% 24.7B
Weighted average by Cap. -1.74%+4.34%+92.64%+132.53%

Financials

2026 *2027 *
Net sales 2.5M 3.33M 2.92M 2.7M 4.73M 319M 4.82M 32.46M 12.61M 156M 12.52M 12.25M 542M 3.44M 4.6M 4.03M 3.72M 6.52M 440M 6.65M 44.76M 17.39M 215M 17.27M 16.89M 748M
Net income -50.34M -67.27M -59.01M -54.48M -95.41M -6.44B -97.32M -655M -254M -3.15B -253M -247M -10.94B -84.67M -113M -99.24M -91.62M -160M -10.83B -164M -1.1B -428M -5.3B -425M -416M -18.4B
Net Debt -146M -196M -172M -158M -278M -18.74B -283M -1.91B -740M -9.17B -735M -719M -31.83B -249M -333M -292M -270M -473M -31.92B -482M -3.24B -1.26B -15.62B -1.25B -1.22B -54.22B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
08/07/26 $9.550 -5.91% 102,958
07/07/26 $10.15 -4.06% 617,739
06/07/26 $10.58 +1.83% 578,918
02/07/26 $10.39 -1.05% 696,727
01/07/26 $10.50 -4.37% 718,986
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.15USD
Average target price
29.17USD
Spread / Average Target
+187.36%

Quarterly revenue - Rate of surprise